Humanized Mouse and Rat Models Market - Global Forecast to 2030
商品番号 : SMB-33696
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年4月 |
| ページ数 | 255 |
| 図表数 | 309 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global humanized mouse and rat model market is anticipated to reach USD 409.8 million in 2030 from USD 276.2 million in 2025, with a significant CAGR of 8.2%.
世界のヒト化マウス・ラットモデル市場は、2025年の2億7,620万米ドルから2030年には4億980万米ドルに達し、8.2%という大幅なCAGRで成長すると予想されています。
The market is growing strongly at a high CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players will likely witness healthy growth opportunities due to technological advancements, new drug discovery techniques, patent expirations, and rising demand for specialized testing services among end users.
製薬企業およびバイオ医薬品企業による研究開発投資の増加により、市場は高いCAGRで力強く成長しています。研究開発パイプラインの拡大に伴い、希少疾患やオーファンドラッグに関する研究活動に加え、分析試験のアウトソーシング需要も増加すると予想されます。さらに、自社開発における医薬品開発コストの高騰もこの傾向に拍車をかけています。業界関係者は、技術の進歩、新たな創薬技術、特許満了、そしてエンドユーザーによる専門的な試験サービスへの需要の高まりにより、健全な成長機会を享受できる可能性が高いでしょう。
“Humanized mouse model segment dominated the type segment in 2024”
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2024, humanized mouse models will have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with the fastest CAGR through the forecast period. An increase in demand for cell-based humanized mouse models has contributed to the segment’s growth. These models are utilized in various applications, including the analysis of the safety and effectiveness of potential new drugs and in long-term studies in immuno-oncology, infectious diseases, and graft-versus-host disease.
“The immunology & infectious diseases segment accounted for the second largest share of the market in 2024”
The humanized mouse and rat model market is segmented based on application into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.
“Pharmaceutical & Biotechnology Companies will likely record the highest CAGR during the forecast period”
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the humanized mouse and rat model market is due to the rising expenditure for innovative drug development and the growing preference for personalized medicine. However, the CROs & CDMOs segment is expected to register the highest growth during the forecast period due to the increasing number of pharmaceutical & biotechnology companies outsourcing preclinical studies and research activities for drug development to this end user segment.
“US to record the highest CAGR during the forecast period”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the humanized mouse and rat model market in 2024 and is estimated to continue dominating during the forecast period. The US leads the North American market, driven by the presence of key players. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth.
In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the humanized mouse and rat model market.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 55%, Tier 2 – 25%, and Tier 3 – 20%
- By Designation: C-level Executives – 45%, Directors – 30%, and Others – 25%
- By Region: North America – 45%, Europe – 30%, Asia Pacific – 20%, Latin America – 3% and Middle East & Africa – 2%
Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), JSR Corporation (US) (Crown Biosciences), Champions Oncology, Inc. (US), CLEA Japan Inc. (Japan), genOway (France), Inotiv (US), Janvier Labs (France), Altogen Labs (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), Reaction Biology (US), Harbour BioMed (Netherlands), Oncodesign Services (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US) are some of the key players in the humanized mouse and rat model market.
Research Coverage:
Humanized mouse and rat model market report is segmented based on type {[(humanized mouse models {genetic humanized mouse models and cell-based humanized mouse models (CD34 humanized mouse models, PBMC humanized mouse models, and BLT humanized mouse models)]} and humanized rat models), application (oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications, end user (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East, Africa).
The report’s scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the humanized mouse and rat model market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This includes information about recent product launches, collaborations, acquisitions, and humanized mouse and rat model market developments.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the humanized mouse and rat model and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising use of humanized models in drug discovery research, emerging preclinical applications of humanized mouse models, government-funded initiatives for cancer research, and increasing R&D activities in the pharmaceutical & biotechnology industry), restraints (introduction of FDA Modernization Act 2.0/3.0, stringent regulatory compliance for ethical use of animal models), opportunities (growing preference for humanized PDX models, emergence of CRISPR in biomedical research), and challenges (alternatives for animal testing, limitations of humanized mouse models) influencing market growth.
- Product Development/Innovation: Detailed insights on upcoming technologies in humanized mouse and rat models, research and development activities, and new product launches in the humanized mouse and rat model market.
- Market Development: Comprehensive information about lucrative markets—the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Inotiv (US), and genOway (France).
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.3 INCLUSIONS AND EXCLUSIONS 28
1.4 STUDY SCOPE 29
1.4.1 MARKET SEGMENTATION AND REGIONS COVERED 29
1.4.2 YEARS CONSIDERED 30
1.4.3 CURRENCY CONSIDERED 30
1.5 STAKEHOLDERS 30
1.6 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
2.1.1 SECONDARY DATA 33
2.1.1.1 Objectives of secondary research 33
2.1.2 PRIMARY DATA 34
2.1.2.1 Objectives of primary research 34
2.2 MARKET SIZE ESTIMATION 35
2.2.1 GLOBAL MARKET ESTIMATION 35
2.2.2 SEGMENTAL MARKET ESTIMATION 38
2.3 GROWTH RATE PROJECTIONS 39
2.4 DATA TRIANGULATION 41
2.5 RESEARCH ASSUMPTIONS 42
2.6 RESEARCH LIMITATIONS 43
2.7 RISK ANALYSIS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 47
4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW 47
4.2 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER AND COUNTRY, 2024 48
4.3 HUMANIZED MOUSE AND RAT MODEL MARKET, BY KEY COUNTRY 49
4.4 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
5.2.1 DRIVERS 51
5.2.1.1 Rising use of humanized models in drug discovery research 51
5.2.1.2 Emerging preclinical applications of humanized mouse models 53
5.2.1.3 Government-funded initiatives for cancer research 53
5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industry 54
5.2.2 RESTRAINTS 55
5.2.2.1 Introduction of FDA Modernization Act 2.0/3.0 55
5.2.2.2 Stringent regulatory compliance for ethical use of animal models 55
5.2.3 OPPORTUNITIES 56
5.2.3.1 Growing preference for humanized PDX models 56
5.2.3.2 Emergence of CRISPR in biomedical research 56
5.2.4 CHALLENGES 57
5.2.4.1 Alternative methods for animal testing 57
5.2.4.2 Limitations of humanized mouse models 57
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 58
5.4 PRICING ANALYSIS 59
5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS,
BY KEY PLAYER, 2022–2024 59
5.4.2 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION 60
5.5 SUPPLY CHAIN ANALYSIS 62
5.6 VALUE CHAIN ANALYSIS 63
5.7 ECOSYSTEM ANALYSIS 65
5.8 INVESTMENT AND FUNDING SCENARIO 67
5.9 TECHNOLOGY ANALYSIS 68
5.9.1 KEY TECHNOLOGIES 68
5.9.1.1 CRISPR-Cas9 68
5.9.1.2 Tissue engineering 68
5.9.1.3 In vivo imaging 69
5.9.2 COMPLEMENTARY TECHNOLOGIES 69
5.9.2.1 3D cell culture 69
5.9.2.2 Organs-on-Chips 69
5.9.2.3 Biomarker discovery 69
5.9.3 ADJACENT TECHNOLOGIES 70
5.9.3.1 Proteomics 70
5.9.3.2 Microfluidics 70
5.9.3.3 Regenerative medicine 70
5.10 PATENT ANALYSIS 70
5.11 TRADE ANALYSIS 74
5.12 KEY CONFERENCES AND EVENTS, 2025–2026 76
5.13 REGULATORY LANDSCAPE 76
5.13.1 REGULATORY FRAMEWORK 76
5.13.2 NORTH AMERICA 76
5.13.3 EUROPE 77
5.13.4 ASIA PACIFIC 79
5.13.4.1 China 79
5.13.4.2 Japan 79
5.13.4.3 India 80
5.13.4.4 Australia 80
5.13.5 LATIN AMERICA 81
5.13.6 MIDDLE EAST & AFRICA 81
5.13.7 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
5.14 PORTER’S FIVE FORCES ANALYSIS 83
5.14.1 THREAT OF NEW ENTRANTS 84
5.14.2 THREAT OF SUBSTITUTES 84
5.14.3 BARGAINING POWER OF SUPPLIERS 85
5.14.4 BARGAINING POWER OF BUYERS 85
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 85
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 85
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 85
5.15.2 KEY BUYING CRITERIA, BY END USER 86
5.16 IMPACT OF AI ON HUMANIZED MOUSE AND RAT MODEL MARKET 87
5.16.1 INTRODUCTION 87
5.16.2 MARKET POTENTIAL OF AI IN HUMANIZED MOUSE AND RAT MODELS 87
5.16.3 AI USE CASES 88
5.16.4 KEY COMPANIES IMPLEMENTING AI 88
5.16.5 FUTURE OF GENERATIVE AI IN HUMANIZED MOUSE AND RAT MODEL MARKET 88
6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE 89
6.1 INTRODUCTION 90
6.2 HUMANIZED MOUSE MODELS 91
6.2.1 GENETIC HUMANIZED MOUSE MODELS 94
6.2.1.1 Advancements in genetical engineering technologies to drive market 94
6.2.2 CELL-BASED HUMANIZED MOUSE MODELS 96
6.2.2.1 CD34 humanized mouse models 98
6.2.2.1.1 Rising demand for stem cell therapy to propel market 98
6.2.2.2 PBMC humanized mouse models 100
6.2.2.2.1 Growing prevalence of infectious diseases to boost demand 100
6.2.2.3 BLT humanized mouse models 103
6.2.2.3.1 Surge in HIV cases to drive market 103
6.3 HUMANIZED RAT MODELS 105
6.3.1 PREFERENCE FOR SRG RAT MODELS FOR RESEARCH STUDIES WITH LARGE SAMPLE SIZE SUPPORTS THE SEGMENT GROWTH 105
7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER 107
7.1 INTRODUCTION 108
7.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 108
7.2.1 GROWING ADOPTION OF HU-MICE MODELS IN VACCINE DEVELOPMENT TO BOOST SEGMENT GROWTH 108
7.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS 111
7.3.1 OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET 111
7.4 ACADEMIC & RESEARCH INSTITUTES 113
7.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET 113
8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION 116
8.1 INTRODUCTION 117
8.2 ONCOLOGY 117
8.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO DRIVE MARKET 117
8.3 IMMUNOLOGY AND INFECTIOUS DISEASES 120
8.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET 120
8.4 NEUROSCIENCE 122
8.4.1 RISING INCIDENCE OF CNS DISORDERS TO DRIVE MARKET 122
8.5 TOXICOLOGY 124
8.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH 124
8.6 HEMATOPOIESIS 126
8.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET 126
8.7 OTHER APPLICATIONS 128
9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION 131
9.1 INTRODUCTION 132
9.2 NORTH AMERICA 133
9.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA 136
9.2.2 US 136
9.2.2.1 Growing research initiatives on mAbs and biosimilars to drive market 136
9.2.3 CANADA 139
9.2.3.1 Government initiatives on stem cell research to drive market 139
9.3 EUROPE 141
9.3.1 MACROECONOMIC OUTLOOK OF EUROPE 143
9.3.2 GERMANY 145
9.3.2.1 Rising pharmaceutical R&D expenditure to drive market 145
9.3.3 UK 147
9.3.3.1 Growing investments in cancer research to drive market 147
9.3.4 FRANCE 149
9.3.4.1 Rising initiatives for genomics research to support market growth 149
9.3.5 ITALY 151
9.3.5.1 Robust pharmaceutical production to fuel market 151
9.3.6 SPAIN 153
9.3.6.1 Rising growth in biotech industry to drive market 153
9.3.7 REST OF EUROPE 155
9.4 ASIA PACIFIC 157
9.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC 161
9.4.2 CHINA 161
9.4.2.1 High growth in pharmaceutical industry to drive market 161
9.4.3 JAPAN 164
9.4.3.1 Growing research collaborations among pharmaceutical companies to drive market 164
9.4.4 INDIA 166
9.4.4.1 Growth in biotech industry to drive market 166
9.4.5 SOUTH KOREA 169
9.4.5.1 Rising government-funded investments for pharmaceutical R&D to drive market 169
9.4.6 AUSTRALIA 171
9.4.6.1 Rising biomedical research projects to drive market 171
9.4.7 REST OF ASIA PACIFIC 173
9.5 LATIN AMERICA 175
9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET 175
9.5.2 MACROECONOMIC OUTLOOK OF LATIN AMERICA 177
9.6 MIDDLE EAST 178
9.6.1 GROWING PHARMACEUTICAL MARKET IN COUNTRIES TO SUPPORT MARKET GROWTH 178
9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 180
9.7 AFRICA 181
9.7.1 GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH 181
9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 183
10 COMPETITIVE LANDSCAPE 184
10.1 INTRODUCTION 184
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN 184
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET 185
10.3 REVENUE ANALYSIS, 2020−2024 187
10.4 MARKET SHARE ANALYSIS, 2024 187
10.4.1 HUMANIZED MOUSE AND RAT MODEL MARKET 188
10.5 COMPANY VALUATION AND FINANCIAL METRICS 190
10.5.1 FINANCIAL METRICS 190
10.6 BRAND/PRODUCT COMPARISON 191
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 192
10.7.1 STARS 192
10.7.2 EMERGING LEADERS 192
10.7.3 PERVASIVE PLAYERS 192
10.7.4 PARTICIPANTS 192
10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 194
10.7.5.1 Company footprint 194
10.7.5.2 Region footprint 195
10.7.5.3 Type footprint 196
10.7.5.4 Application footprint 197
10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 198
10.8.1 PROGRESSIVE COMPANIES 198
10.8.2 RESPONSIVE COMPANIES 198
10.8.3 DYNAMIC COMPANIES 198
10.8.4 STARTING BLOCKS 198
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES 200
10.8.5.1 Detailed list of key startups/SMEs 200
10.8.5.2 Competitive benchmarking of key startups/SMEs 201
10.9 COMPETITIVE SCENARIO 202
10.9.1 PRODUCT LAUNCHES & APPROVALS 202
10.9.2 DEALS 202
10.9.3 EXPANSIONS 204
11 COMPANY PROFILES 205
11.1 KEY PLAYERS 205
11.1.1 CHARLES RIVER LABORATORIES 205
11.1.1.1 Business overview 205
11.1.1.2 Products offered 206
11.1.1.3 Recent developments 207
11.1.1.3.1 Deals 207
11.1.1.3.2 Other developments 207
11.1.1.4 MnM view 208
11.1.1.4.1 Key strengths 208
11.1.1.4.2 Strategic choices 208
11.1.1.4.3 Weaknesses and competitive threats 208
11.1.2 THE JACKSON LABORATORY 209
11.1.2.1 Business overview 209
11.1.2.2 Products offered 211
11.1.2.3 Recent developments 212
11.1.2.3.1 Deals 212
11.1.2.4 MnM view 212
11.1.2.4.1 Key strengths 212
11.1.2.4.2 Strategic choices 212
11.1.2.4.3 Weaknesses and competitive threats 212
11.1.3 INOTIV 213
11.1.3.1 Business overview 213
11.1.3.2 Products offered 215
11.1.3.3 Recent developments 216
11.1.3.3.1 Deals 216
11.1.3.4 MnM view 217
11.1.3.4.1 Key strengths 217
11.1.3.4.2 Strategic choices 217
11.1.3.4.3 Weaknesses and competitive threats 217
11.1.4 GENOWAY 218
11.1.4.1 Business overview 218
11.1.4.2 Products offered 218
11.1.4.3 Recent developments 220
11.1.4.3.1 Other developments 220
11.1.4.4 MnM view 220
11.1.4.4.1 Key strengths 220
11.1.4.4.2 Strategic choices 220
11.1.4.4.3 Weaknesses and competitive threats 220
11.1.5 TACONIC BIOSCIENCES, INC. 221
11.1.5.1 Business overview 221
11.1.5.2 Products offered 222
11.1.5.3 Recent developments 223
11.1.5.3.1 Product launches 223
11.1.5.3.2 Expansions 223
11.1.6 JSR CORPORATION 224
11.1.6.1 Business overview 224
11.1.6.2 Products offered 225
11.1.6.3 Recent developments 226
11.1.6.3.1 Deals 226
11.1.6.3.2 Expansions 227
11.1.7 CHAMPIONS ONCOLOGY, INC. 228
11.1.7.1 Business overview 228
11.1.7.2 Products offered 229
11.1.8 JANVIER LABS 230
11.1.8.1 Business overview 230
11.1.8.2 Products offered 230
11.1.8.3 Recent developments 231
11.1.8.3.1 Deals 231
11.1.9 VITALSTAR BIOTECHNOLOGY 232
11.1.9.1 Business overview 232
11.1.9.2 Products offered 232
11.1.10 INGENIOUS TARGETING LABORATORY 233
11.1.10.1 Business overview 233
11.1.10.2 Products offered 234
11.1.11 HARBOUR BIOMED 235
11.1.11.1 Business overview 235
11.1.11.2 Products offered 236
11.1.11.3 Recent developments 236
11.1.11.3.1 Deals 236
11.1.12 ONCODESIGN SERVICES 237
11.1.12.1 Business overview 237
11.1.12.2 Products offered 237
11.1.13 PHARMATEST SERVICES 238
11.1.13.1 Business overview 238
11.1.13.2 Products offered 238
11.2 OTHER PLAYERS 239
11.2.1 OZGENE PTY LTD. 239
11.2.2 CLEA JAPAN, INC. 240
11.2.3 ALTOGEN LABS 241
11.2.4 REACTION BIOLOGY 242
11.2.5 TRANSCURE BIOSERVICES 243
11.2.6 CYAGEN 244
11.2.7 ARAGEN LIFE SCIENCES LTD. 245
11.2.8 BIOCYTOGEN 246
11.2.9 GEMPHARMATECH 247
12 APPENDIX 248
12.1 DISCUSSION GUIDE 248
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 251
12.3 CUSTOMIZATION OPTIONS 253
12.4 RELATED REPORTS 253
12.5 AUTHOR DETAILS 254
LIST OF TABLES
TABLE 1 HUMANIZED MOUSE AND RAT MODEL MARKET: INCLUSIONS AND EXCLUSIONS 28
TABLE 2 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS 40
TABLE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RISK ANALYSIS 43
TABLE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: IMPACT ANALYSIS OF
MARKET DYNAMICS 51
TABLE 5 NUMBER OF R&D PRODUCTS, BY INDICATION (2024) 54
TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022–2024 (USD MILLION) 59
TABLE 7 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION,
2022–2024 (USD) 60
TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS (HUMANIZED MOUSE MODELS), BY REGION, 2022–2024 (USD) 61
TABLE 9 HUMANIZED MOUSE AND RAT MODEL MARKET: ROLE OF COMPANIES IN ECOSYSTEM 66
TABLE 10 INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021−2025 67
TABLE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: INNOVATIONS AND
PATENT REGISTRATIONS, 2021–2024 72
TABLE 12 IMPORT DATA FOR LABORATORY MOUSE 74
TABLE 13 EXPORT DATA FOR LABORATORY MOUSE 75
TABLE 14 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES
AND EVENTS, 2025–2026 76
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 83
TABLE 19 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS 83
TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 86
TABLE 21 KEY BUYING CRITERIA, BY END USER 86
TABLE 22 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,
2023–2030 (USD MILLION) 90
TABLE 23 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,
2023–2030 (THOUSAND UNITS) 90
TABLE 24 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 92
TABLE 25 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 93
TABLE 26 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 93
TABLE 27 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 93
TABLE 28 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 94
TABLE 29 GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION,
2023–2030 (USD MILLION) 95
TABLE 30 NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 95
TABLE 31 EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 95
TABLE 32 ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 96
TABLE 33 CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 96
TABLE 34 CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY REGION, 2023–2030 (USD MILLION) 97
TABLE 35 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 97
TABLE 36 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 97
TABLE 37 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 98
TABLE 38 CD34 HUMANIZED MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 99
TABLE 39 NORTH AMERICA: CD34 HUMANIZED MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 99
TABLE 40 EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 100
TABLE 41 ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 100
TABLE 42 PBMC HUMANIZED MICE MODELS MARKET, BY REGION,
2023–2030 (USD MILLION) 101
TABLE 43 NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 44 EUROPE: PBMC HUMANIZED MICE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 45 ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 46 BLT HUMANIZED MOUSE MODELS MARKET, BY REGION,
2023–2030 (USD MILLION) 103
TABLE 47 NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 48 EUROPE: BLT HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 49 ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 50 HUMANIZED RAT MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 105
TABLE 51 NORTH AMERICA: HUMANIZED RAT MODELS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 52 EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 106
TABLE 53 ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 106
TABLE 54 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER,
2023–2030 (USD MILLION) 108
TABLE 55 USE OF HUMANIZED MICE MODELS IN DEVELOPED AND TESTED VACCINES 109
TABLE 56 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 57 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 58 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 59 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 60 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS,
BY REGION, 2023–2030 (USD MILLION) 112
TABLE 61 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS
AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 62 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 63 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS
AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 64 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 114
TABLE 65 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 66 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 67 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 68 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 117
TABLE 69 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY,
BY REGION, 2023–2030 (USD MILLION) 119
TABLE 70 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 71 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 72 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 73 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY
AND INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 121
TABLE 74 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 75 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY
AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 76 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 77 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE,
BY REGION, 2023–2030 (USD MILLION) 123
TABLE 78 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 79 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE,
BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 80 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 81 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY,
BY REGION, 2023–2030 (USD MILLION) 125
TABLE 82 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 83 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 84 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 85 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS,
BY REGION, 2023–2030 (USD MILLION) 127
TABLE 86 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET
FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 87 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS,
BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 88 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 89 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 129
TABLE 90 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET
FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 91 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 92 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 93 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION,
2023–2030 (USD MILLION) 132
TABLE 94 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 95 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 134
TABLE 96 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 134
TABLE 97 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 98 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 135
TABLE 99 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 135
TABLE 100 KEY MACROECONOMIC INDICATORS OF NORTH AMERICA 136
TABLE 101 US: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 137
TABLE 102 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 137
TABLE 103 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 138
TABLE 104 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 138
TABLE 105 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER,
2023–2030 (USD MILLION) 138
TABLE 106 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,
2023–2030 (USD MILLION) 139
TABLE 107 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,
2023–2030 (USD MILLION) 140
TABLE 108 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 140
TABLE 109 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 140
TABLE 110 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 141
TABLE 111 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 112 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 113 EUROPE: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 114 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 115 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 143
TABLE 116 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 143
TABLE 117 KEY MACROECONOMIC INDICATORS OF EUROPE 144
TABLE 118 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 145
TABLE 119 GERMANY: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 145
TABLE 120 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 146
TABLE 121 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 146
TABLE 122 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 146
TABLE 123 UK: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 147
TABLE 124 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 147
TABLE 125 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 148
TABLE 126 UK: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 148
TABLE 127 UK: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 148
TABLE 128 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 149
TABLE 129 FRANCE: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 130 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 131 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 150
TABLE 132 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 151
TABLE 133 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 152
TABLE 134 ITALY: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 152
TABLE 135 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 152
TABLE 136 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 153
TABLE 137 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 153
TABLE 138 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 139 SPAIN: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 140 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 141 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 155
TABLE 142 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 155
TABLE 143 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 144 REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 145 REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 146 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 157
TABLE 147 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 157
TABLE 148 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 149 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 150 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 151 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 160
TABLE 152 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 160
TABLE 153 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 160
TABLE 154 KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC 161
TABLE 155 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 162
TABLE 156 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,
2023–2030 (USD MILLION) 163
TABLE 157 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 163
TABLE 158 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 163
TABLE 159 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 164
TABLE 160 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 165
TABLE 161 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE,
2023–2030 (USD MILLION) 165
TABLE 162 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 165
TABLE 163 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 166
TABLE 164 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 166
TABLE 165 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 167
TABLE 166 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,
2023–2030 (USD MILLION) 167
TABLE 167 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 168
TABLE 168 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 168
TABLE 169 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 168
TABLE 170 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 171 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 172 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 173 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 170
TABLE 174 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 171
TABLE 175 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 171
TABLE 176 AUSTRALIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,
2023–2030 (USD MILLION) 172
TABLE 177 AUSTRALIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 178 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 172
TABLE 179 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 173
TABLE 180 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 173
TABLE 181 REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 173
TABLE 182 REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 174
TABLE 183 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 174
TABLE 184 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 174
TABLE 185 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 186 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 187 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 176
TABLE 188 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 176
TABLE 189 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 176
TABLE 190 KEY MACROECONOMIC INDICATORS OF LATIN AMERICA 177
TABLE 191 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 192 MIDDLE EAST: HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 193 MIDDLE EAST: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 194 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 179
TABLE 195 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 179
TABLE 196 KEY MACROECONOMIC INDICATORS OF MIDDLE EAST 180
TABLE 197 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 198 AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,
2023–2030 (USD MILLION) 181
TABLE 199 AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 182
TABLE 200 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 182
TABLE 201 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET,
BY END USER, 2023–2030 (USD MILLION) 182
TABLE 202 KEY MACROECONOMIC INDICATORS OF AFRICA 183
TABLE 203 STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE
AND RAT MODEL MARKET, 2021−2024 185
TABLE 204 HUMANIZED MOUSE AND RAT MODEL MARKET: DEGREE OF COMPETITION 188
TABLE 205 HUMANIZED MOUSE AND RAT MODEL MARKET: REGION FOOTPRINT 195
TABLE 206 HUMANIZED MOUSE AND RAT MODEL MARKET: TYPE FOOTPRINT 196
TABLE 207 HUMANIZED MOUSE AND RAT MODEL MARKET: APPLICATION FOOTPRINT 197
TABLE 208 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STARTUPS/SMES 200
TABLE 209 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPETITIVE BENCHMARKING
OF KEY START UPS/SMES 201
TABLE 210 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES,
JANUARY 2021–MARCH 2025 202
TABLE 211 HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS, JANUARY
2021–MARCH 2025 203
TABLE 212 HUMANIZED MOUSE AND RAT MODEL MARKET: EXPANSIONS,
JANUARY 2021–MARCH 2025 204
TABLE 213 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 205
TABLE 214 CHARLES RIVER LABORATORIES: PRODUCTS OFFERED 206
TABLE 215 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JANUARY 2025 207
TABLE 216 CHARLES RIVER LABORATORIES: OTHER DEVELOPMENTS,
JANUARY 2021–JANUARY 2025 207
TABLE 217 THE JACKSON LABORATORY: COMPANY OVERVIEW 209
TABLE 218 THE JACKSON LABORATORY: PRODUCTS OFFERED 211
TABLE 219 THE JACKSON LABORATORY: DEALS, JANUARY 2021–JANUARY 2025 212
TABLE 220 INOTIV: COMPANY OVERVIEW 213
TABLE 221 INOTIV: PRODUCTS OFFERED 215
TABLE 222 INOTIV: DEALS, JANUARY 2021–JANUARY 2025 216
TABLE 223 GENOWAY: COMPANY OVERVIEW 218
TABLE 224 GENOWAY: PRODUCTS OFFERED 218
TABLE 225 GENOWAY: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 220
TABLE 226 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW 221
TABLE 227 TACONIC BIOSCIENCES, INC.: PRODUCTS OFFERED 222
TABLE 228 TACONIC BIOSCIENCES, INC.: PRODUCT LAUNCHES,
JANUARY 2021–JANUARY 2025 223
TABLE 229 TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025 223
TABLE 230 JSR CORPORATION: COMPANY OVERVIEW 224
TABLE 231 JSR CORPORATION: PRODUCTS OFFERED 225
TABLE 232 JSR CORPORATION: DEALS, JANUARY 2021–JANUARY 2025 226
TABLE 233 JSR CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025 227
TABLE 234 CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW 228
TABLE 235 CHAMPIONS ONCOLOGY, INC.: PRODUCTS OFFERED 229
TABLE 236 JANVIER LABS: COMPANY OVERVIEW 230
TABLE 237 JANVIER LABS: PRODUCTS OFFERED 230
TABLE 238 JANVIER LABS: DEALS, JANUARY 2021–JANUARY 2025 231
TABLE 239 VITALSTAR BIOTECHNOLOGY: COMPANY OVERVIEW 232
TABLE 240 VITALSTAR BIOTECHNOLOGY: PRODUCTS OFFERED 232
TABLE 241 INGENIOUS TARGETING LABORATORY: COMPANY OVERVIEW 233
TABLE 242 INGENIOUS TARGETING LABORATORY: PRODUCTS OFFERED 234
TABLE 243 HARBOUR BIOMED: COMPANY OVERVIEW 235
TABLE 244 HARBOUR BIOMED: PRODUCTS OFFERED 236
TABLE 245 HARBOUR BIOMED: DEALS, JANUARY 2021–JANUARY 2025 236
TABLE 246 ONCODESIGN SERVICES: COMPANY OVERVIEW 237
TABLE 247 ONCODESIGN SERVICES: PRODUCTS OFFERED 237
TABLE 248 PHARMATEST SERVICES: COMPANY OVERVIEW 238
TABLE 249 PHARMATEST SERVICES: PRODUCTS OFFERED 238
TABLE 250 OZGENE PTY LTD.: COMPANY OVERVIEW 239
TABLE 251 CLEA JAPAN, INC.: COMPANY OVERVIEW 240
TABLE 252 ALTOGEN LABS: COMPANY OVERVIEW 241
TABLE 253 REACTION BIOLOGY: COMPANY OVERVIEW 242
TABLE 254 TRANSCURE BIOSERVICES: COMPANY OVERVIEW 243
TABLE 255 CYAGEN: COMPANY OVERVIEW 244
TABLE 256 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW 245
TABLE 257 BIOCYTOGEN: COMPANY OVERVIEW 246
TABLE 258 GEMPHARMATECH: COMPANY OVERVIEW 247
LIST OF FIGURES
FIGURE 1 HUMANIZED MOUSE AND RAT MODEL MARKET SEGMENTATION AND
REGIONS CONSIDERED 29
FIGURE 2 HUMANIZED MOUSE AND RAT MODEL MARKET: YEARS CONSIDERED 30
FIGURE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RESEARCH DESIGN 32
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT,
DESIGNATION, AND REGION 34
FIGURE 5 GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET SIZE ESTIMATION, 2024 35
FIGURE 6 COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024 36
FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024 36
FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARIES 38
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 38
FIGURE 10 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS, 2025–2030 40
FIGURE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: DATA TRIANGULATION 41
FIGURE 12 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,
2025 VS. 2030 (USD MILLION) 44
FIGURE 13 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 45
FIGURE 14 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 45
FIGURE 15 REGIONAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL
MARKET, 2025–2030 46
FIGURE 16 RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH
TO DRIVE MARKET 47
FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED
FOR LARGEST MARKET SHARE IN US IN 2024 48
FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 49
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024 49
FIGURE 20 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
FIGURE 21 NUMBER OF CLINICAL TRIALS REGISTERED FOR CANCER IMMUNOTHERAPIES, 2020–2024 52
FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 58
FIGURE 23 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022–2024 (USD) 59
FIGURE 24 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION,
2022–2024 (USD) 60
FIGURE 25 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION,
2022–2024 (USD) 61
FIGURE 26 HUMANIZED MOUSE AND RAT MODEL MARKET: SUPPLY CHAIN ANALYSIS 63
FIGURE 27 HUMANIZED MOUSE AND RAT MODEL MARKET: VALUE CHAIN ANALYSIS 63
FIGURE 28 HUMANIZED MOUSE AND RAT MODEL MARKET ECOSYSTEM 66
FIGURE 29 INVESTMENT AND FUNDING SCENARIO, 2021–2025 68
FIGURE 30 HUMANIZED MOUSE AND RAT MODEL MARKET: PATENT ANALYSIS, 2014–2024 71
FIGURE 31 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS 84
FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 85
FIGURE 33 KEY BUYING CRITERIA, BY END USER 86
FIGURE 34 AI USE CASES 88
FIGURE 35 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,
2023–2030 (THOUSAND UNITS) 91
FIGURE 36 HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT 133
FIGURE 37 HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT 158
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN HUMANIZED MOUSE AND
RAT MODEL MARKET, 2020−2024 187
FIGURE 39 MARKET SHARE ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL
MARKET, 2024 188
FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS, 2024 190
FIGURE 41 COMPANY VALUATION AND FINANCIAL METRICS, 2024 190
FIGURE 42 HUMANIZED MOUSE AND RAT MODEL MARKET: BRAND/PRODUCT COMPARISON 191
FIGURE 43 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION
MATRIX (KEY PLAYERS), 2024 193
FIGURE 44 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY FOOTPRINT 194
FIGURE 45 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 199
FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024) 206
FIGURE 47 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2024) 210
FIGURE 48 INOTIV: COMPANY SNAPSHOT (2024) 214
FIGURE 49 JSR CORPORATION: COMPANY SNAPSHOT (2024) 224
FIGURE 50 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2024) 228
FIGURE 51 HARBOUR BIOMED: COMPANY SNAPSHOT (2024) 235
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- UV安定剤市場 – 2030年までの世界予測 2025-05-16
- 産業用通信市場 – 2030年までの世界予測 2025-05-16
- 経腸栄養装置市場 – 2030年までの世界予測 2025-05-15
- データセンターGPU市場 – 2030年までの世界予測 2025-05-15
- ステンレス鋼シームレスパイプ市場 – 2030年までの世界予測 2025-05-15